Aeolus Pharmaceuticals, Inc. AOLS

AOLS Company Overview

Aeolus Pharmaceuticals, Inc. (formerly traded under NASDAQ ticker: AOLS) was a U.S.-based biopharmaceutical company focused on the development of catalytic antioxidant compounds intended to reduce tissue damage caused by oxidative stress, radiation exposure, and inflammatory disease processes. The company operated within the biotechnology and specialty pharmaceutical sectors, with research efforts centered primarily on radiation countermeasures and pulmonary indications. Its lead development candidate, AEOL 10150, was investigated for potential use in mitigating radiation-induced injury and related medical conditions.

The company’s business model was largely research and development driven rather than commercial-product based, with funding historically supported through government contracts, grants, licensing activity, and capital markets financing. Public filings and historical investor materials indicate that Aeolus positioned itself around specialized antioxidant chemistry with potential applications in biodefense and emergency medical preparedness. The company evolved from an early-stage pharmaceutical research organization into a niche biotechnology developer with a concentrated pipeline strategy. Publicly available information regarding ongoing operations, current commercialization activity, or active exchange listing status is limited, and some operational data is inconclusive based on available public sources.